Literature DB >> 10233947

Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone.

M D Robek1, L Ratner.   

Abstract

The human T-cell leukemia virus type 1 (HTLV-1) transcriptional trans-activator Tax has been demonstrated to have transforming activity in multiple cell culture and transgenic-mouse models. In addition to activating transcription from the viral long terminal repeat (LTR) through the cyclic AMP response element binding protein/activating transcription factor (CREB/ATF) family of transcription factors, Tax activates the expression of multiple cellular promoters through the NF-kappaB pathway of transcriptional activation. The Tax mutants M22 and M47 have previously been demonstrated to selectively abrogate the ability of Tax to activate transcription through the NF-kappaB or CREB/ATF pathway, respectively. These mutations were introduced in the tax gene of the ACH functional molecular clone of HTLV-1, and virus produced from the mutant ACH clones was examined for the ability to replicate and immortalize primary human lymphocytes. While virus derived from the clone containing the M47 mutation retained the ability to immortalize T lymphocytes, the M22 mutant lost the ability to immortalize infected cells. These results indicate that activation of the CREB/ATF pathway by Tax is dispensable for the immortalization of T cells by HTLV-1, whereas activation of the NF-kappaB pathway may be critical.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233947      PMCID: PMC112529     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Interaction of HTLV-1 Tax1 with p67SRF causes the aberrant induction of cellular immediate early genes through CArG boxes.

Authors:  M Fujii; H Tsuchiya; T Chuhjo; T Akizawa; M Seiki
Journal:  Genes Dev       Date:  1992-11       Impact factor: 11.361

3.  Transcriptional activator Tax of HTLV-1 binds to the NF-kappa B precursor p105.

Authors:  H Hirai; J Fujisawa; T Suzuki; K Ueda; M Muramatsu; A Tsuboi; N Arai; M Yoshida
Journal:  Oncogene       Date:  1992-09       Impact factor: 9.867

4.  Phenotypic diversity and prognosis of adult T-cell leukemia.

Authors:  S Kamihira; H Sohda; S Atogami; K Toriya; Y Yamada; K Tsukazaki; S Momita; S Ikeda; M Kusano; T Amagasaki
Journal:  Leuk Res       Date:  1992       Impact factor: 3.156

5.  Characterization of peripheral blood T-lymphocytes transduced with HTLV-I Tax mutants with different trans-activating phenotypes.

Authors:  T Akagi; H Ono; H Nyunoya; K Shimotohno
Journal:  Oncogene       Date:  1997-05-01       Impact factor: 9.867

6.  Transcriptional suppression of the human T-cell leukemia virus type I long terminal repeat occurs by an unconventional interaction of a CREB factor with the R region.

Authors:  X Xu; D A Brown; I Kitajima; J Bilakovics; L W Fey; M I Nerenberg
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

7.  Tax protein of human T-cell leukemia virus type I binds to the ankyrin motifs of inhibitory factor kappa B and induces nuclear translocation of transcription factor NF-kappa B proteins for transcriptional activation.

Authors:  H Hirai; T Suzuki; J Fujisawa; J Inoue; M Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  A trans-activator Tax of human T-cell leukemia virus type 1 binds to NF-kappa B p50 and serum response factor (SRF) and associates with enhancer DNAs of the NF-kappa B site and CArG box.

Authors:  T Suzuki; H Hirai; J Fujisawa; T Fujita; M Yoshida
Journal:  Oncogene       Date:  1993-09       Impact factor: 9.867

9.  Mutational analysis of human T-cell leukemia virus type I Tax: regions necessary for function determined with 47 mutant proteins.

Authors:  O J Semmes; K T Jeang
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B.

Authors:  I Kitajima; T Shinohara; J Bilakovics; D A Brown; X Xu; M Nerenberg
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

View more
  102 in total

1.  Discordance between bovine leukemia virus tax immortalization in vitro and oncogenicity in vivo.

Authors:  J C Twizere; P Kerkhofs; A Burny; D Portetelle; R Kettmann; L Willems
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Immortalization of T lymphocytes by human T-cell leukemia virus type 1 is independent of the tax-CBP/p300 interaction.

Authors:  M D Robek; L Ratner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 3.  Adult T cell leukemia lymphoma.

Authors:  Lee Ratner
Journal:  Front Biosci       Date:  2004-09-01

Review 4.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

5.  The HTLV-1 hbz antisense gene indirectly promotes tax expression via down-regulation of p30(II) mRNA.

Authors:  Gunjan Choudhary; Lee Ratner
Journal:  Virology       Date:  2010-12-21       Impact factor: 3.616

Review 6.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

Review 7.  The human T-cell leukemia virus Rex protein.

Authors:  Ihab Younis; Patrick L Green
Journal:  Front Biosci       Date:  2005-01-01

8.  Cooperation of NF-kappaB2/p100 activation and the PDZ domain binding motif signal in human T-cell leukemia virus type 1 (HTLV-1) Tax1 but not HTLV-2 Tax2 is crucial for interleukin-2-independent growth transformation of a T-cell line.

Authors:  Masaya Higuchi; Chikako Tsubata; Rie Kondo; Sakiko Yoshida; Masahiko Takahashi; Masayasu Oie; Yuetsu Tanaka; Renaud Mahieux; Masao Matsuoka; Masahiro Fujii
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 9.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 10.  Pathogenesis and treatment of human T-cell leukemia virus infection.

Authors:  Lee Ratner
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.